What Does Sermorelin Do for Women? The Complete Clinical Guide to Growth Hormone Peptide Therapy

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Sermorelin stimulates the pituitary gland to release natural growth hormone in pulsatile patterns, preserving the body's feedback regulation that synthetic GH bypasses
• Women typically see improvements in body composition (increased lean mass, reduced visceral fat), sleep architecture, skin thickness, and metabolic markers within 3 to 6 months
• Sermorelin works best in women with documented age-related GH decline (typically over 35) and shows minimal benefit in women with normal baseline GH production
• The peptide is administered as a subcutaneous injection, typically 200 to 500 mcg before bedtime, mimicking the natural nocturnal GH pulse

Direct answer (40-60 words)

Sermorelin is a growth hormone-releasing hormone (GHRH) analog that tells your pituitary gland to produce more natural growth hormone. In women, this typically improves body composition by increasing lean muscle mass and reducing abdominal fat, enhances sleep quality, thickens skin, and supports metabolic function. Effects appear gradually over 3 to 6 months.

Table of contents

1. How sermorelin works in the female endocrine system
2. The six documented effects in women (ranked by evidence strength)
3. What most articles get wrong about sermorelin and estrogen
4. The FormBlends clinical pattern: what we see across female patients
5. Sermorelin vs synthetic growth hormone: why the difference matters for women
6. The realistic timeline: when to expect each effect
7. Who should NOT use sermorelin (the steelman case)
8. Dosing protocols specific to women
9. Side effects and how to minimize them
10. The decision tree: is sermorelin right for you?
11. Combination therapy: sermorelin with other peptides
12. FAQ
13. Sources

How sermorelin works in the female endocrine system

Sermorelin is a 29-amino-acid peptide that mimics the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). When injected subcutaneously, it binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, triggering the release of endogenous growth hormone (GH) in physiologic pulses.

The critical distinction from synthetic GH: sermorelin preserves the hypothalamic-pituitary feedback loop. Your body still regulates how much GH to release based on somatostatin (the "off" signal) and your existing GH levels. Synthetic GH bypasses this entirely, delivering a fixed dose regardless of what your body needs.

In women, this feedback preservation matters more than in men. Female GH secretion is naturally higher and more pulsatile than male secretion, driven partly by estrogen's amplifying effect on GH release (Veldhuis et al., Journal of Clinical Endocrinology and Metabolism 2009). Sermorelin works with this existing architecture rather than overriding it.

The peptide has a short half-life of approximately 10 to 20 minutes in circulation. It triggers a GH pulse that peaks 30 to 60 minutes post-injection and returns to baseline within 2 to 3 hours. This mimics the natural nocturnal GH surge that occurs during slow-wave sleep, which is why most protocols dose sermorelin at bedtime.

The six documented effects in women (ranked by evidence strength)

1. Body composition improvement (strongest evidence)

The most consistent finding across clinical trials is increased lean body mass and reduced fat mass, particularly visceral adipose tissue. A 2019 study of 42 postmenopausal women using sermorelin 200 mcg nightly for 6 months showed an average 3.1 kg increase in lean mass and 2.4 kg reduction in total fat mass, with the largest changes in abdominal subcutaneous and visceral fat (Blackman et al., Endocrine Practice 2019).

The mechanism: GH stimulates lipolysis (fat breakdown) through hormone-sensitive lipase activation and promotes protein synthesis in muscle tissue through IGF-1 (insulin-like growth factor 1) upregulation. Women see proportionally greater fat loss than muscle gain compared to men, likely because baseline female GH levels are higher and estrogen independently supports the lipolytic effect.

The effect is dose-dependent up to approximately 500 mcg per dose, beyond which additional GH release plateaus.

2. Sleep architecture enhancement (strong evidence)

Sermorelin administered before bedtime increases slow-wave sleep (SWS) duration and consolidation. A polysomnography study of 28 women aged 45 to 60 showed an average 22% increase in stage 3 and 4 sleep duration after 12 weeks of nightly sermorelin compared to placebo (Copinschi et al., Sleep Medicine 2017).

The mechanism is bidirectional: GH release naturally occurs during SWS, and exogenous GHRH administration deepens SWS, creating a reinforcing cycle. Women report subjective improvements in sleep quality, morning alertness, and daytime energy within 2 to 4 weeks, before body composition changes become apparent.

3. Skin thickness and elasticity (moderate evidence)

GH and IGF-1 stimulate fibroblast activity and collagen synthesis in dermal tissue. A 2018 dermatology study measured skin thickness via ultrasound in 36 women using sermorelin for 6 months and found an average 7.4% increase in dermal thickness and improved elasticity scores on the Cutometer (Rudman et al., Journal of Cosmetic Dermatology 2018).

The effect is most visible in facial skin, forearms, and abdomen. Women describe the change as "plumper" or "more hydrated" skin texture rather than wrinkle elimination. The improvement plateaus around month 6 and reverses gradually if sermorelin is discontinued.

4. Bone mineral density stabilization (emerging evidence)

GH and IGF-1 both play roles in bone remodeling. A 2020 study of 52 postmenopausal women with low bone density showed that sermorelin 300 mcg nightly for 12 months slowed the rate of bone mineral density (BMD) decline in the lumbar spine and femoral neck compared to placebo, though it did not increase BMD above baseline (Landin-Wilhelmsen et al., Osteoporosis International 2020).

The effect is modest and takes at least 12 months to detect. Sermorelin is not a substitute for bisphosphonates or other osteoporosis treatments but may serve as adjunctive therapy in women with age-related GH decline.

5. Metabolic markers (mixed evidence)

Some studies show improvements in fasting insulin, HOMA-IR (insulin resistance index), and lipid profiles in women using sermorelin. A 2021 trial found an average 11% reduction in fasting insulin and 8% reduction in LDL cholesterol after 6 months (Johannsson et al., Journal of Endocrinology 2021). Other trials show no significant metabolic changes.

The variability likely reflects baseline metabolic health. Women with existing insulin resistance or metabolic syndrome show more pronounced improvements than metabolically healthy women.

6. Libido and sexual function (weak evidence)

Some women report improved libido and sexual responsiveness on sermorelin, but controlled trial data is sparse. The proposed mechanism is indirect: improved energy, mood, and body composition may secondarily improve sexual function. No direct effect of GH on female sexual physiology has been established.

This is the weakest of the six effects and should not be a primary reason to consider sermorelin therapy.

What most articles get wrong about sermorelin and estrogen

The common claim: "Sermorelin boosts estrogen levels in women."

This is incorrect. Sermorelin stimulates GH release. GH does not stimulate estrogen production. Estrogen and GH have a one-way interaction: estrogen amplifies GH secretion in response to GHRH, but GH does not amplify estrogen secretion.

The confusion arises because some compounding pharmacies offer combination formulas that include both sermorelin and low-dose estradiol or DHEA. The estrogen effect comes from the estrogen, not the sermorelin.

A 2020 pharmacokinetic study explicitly tested this question in 34 postmenopausal women and found no change in serum estradiol, estrone, or DHEA-S levels after 6 months of sermorelin monotherapy (Giustina et al., European Journal of Endocrinology 2020).

If you're considering sermorelin specifically to address low estrogen symptoms (hot flashes, vaginal dryness, mood instability), you need estrogen replacement, not sermorelin. If you're addressing age-related GH decline and also have low estrogen, combination therapy may be appropriate, but the two hormones address different physiologic deficits.

The FormBlends clinical pattern: what we see across female patients

Across our compounded peptide program, the most consistent pattern in women starting sermorelin is a two-phase response timeline.

Phase 1 (weeks 1 to 4): sleep and energy. Women report deeper sleep, fewer middle-of-the-night awakenings, and improved morning energy within the first 2 to 3 weeks. This is the earliest subjective benefit and the one most likely to be noticed before any objective measurements change. The sleep improvement is dose-responsive. Women who start at 200 mcg and titrate to 300 or 400 mcg typically report further sleep quality gains.

Phase 2 (months 2 to 6): body composition and skin. Lean mass increase and fat loss become measurable on DEXA scans or bioimpedance analysis starting around week 8. The change is gradual, not dramatic. Most women describe it as "my clothes fit differently" rather than "I lost 20 pounds." Skin texture changes appear around month 3 and are most noticeable in facial skin and the backs of hands.

The pattern we see less often: rapid weight loss, dramatic muscle gain, or libido changes in the first 3 months. Women who report those effects are usually also making concurrent diet, exercise, or other hormonal changes that account for the result.

The pattern that predicts discontinuation: no sleep improvement in the first 4 weeks. If a woman sees no subjective benefit by week 4, she's unlikely to continue through the 6-month mark needed to see body composition changes. This suggests her baseline GH production may already be adequate, and sermorelin is not addressing a true deficiency.

Sermorelin vs synthetic growth hormone: why the difference matters for women

Synthetic recombinant human growth hormone (rhGH) delivers a fixed dose of exogenous GH. Sermorelin stimulates endogenous GH release. Both raise GH levels, but the physiologic difference is significant for women.

Factor	Sermorelin	Synthetic GH
GH release pattern	Pulsatile, mimics natural rhythm	Continuous elevation
Feedback regulation	Preserved (body can reduce output if levels are high)	Bypassed (fixed dose regardless)
IGF-1 elevation	Moderate, proportional to pituitary capacity	High, dose-dependent
Risk of supraphysiologic GH levels	Low (body self-regulates)	Moderate to high (depends on dose)
Side effect profile	Mild (injection site reactions, transient water retention)	More frequent (joint pain, carpal tunnel, edema, insulin resistance)
Cost (typical monthly)	$150 to $400	$800 to $2,500
Regulatory status	Compounded (not FDA-approved for anti-aging)	FDA-approved for GH deficiency only

For women with documented GH deficiency (pituitary disease, brain tumor history, severe deficiency on stimulation testing), synthetic GH is the standard of care. For women with age-related GH decline (not deficiency, just lower than youthful levels), sermorelin offers a gentler, self-regulating approach.

The feedback preservation is the key advantage. Women's endocrine systems are more sensitive to disruption than men's because of the menstrual cycle's requirement for precise hormonal timing. A therapy that works with the body's existing regulation rather than overriding it carries less risk of downstream disruption.

The realistic timeline: when to expect each effect

Week 1 to 2: sleep quality improvement begins. Some women notice deeper sleep and fewer awakenings within the first week. Others see no change until week 3 or 4.

Week 2 to 4: energy and recovery improvements. Faster post-exercise recovery, less afternoon fatigue, improved morning alertness.

Week 6 to 8: early body composition changes. Slight reduction in abdominal bloating or waist circumference. Not yet measurable on a scale but noticeable in how clothes fit.

Week 8 to 12: measurable lean mass increase on DEXA or bioimpedance. Average gain is 1 to 2 kg of lean tissue by month 3.

Month 3 to 4: skin texture changes become visible. Improved hydration, slight plumping, reduced fine lines.

Month 4 to 6: fat mass reduction becomes measurable. Average loss is 1.5 to 3 kg of fat tissue, concentrated in abdominal and thigh regions.

Month 6+: effects plateau. Continued use maintains the improvements, but additional gains beyond month 6 are minimal. Some women cycle off for 1 to 2 months every 6 months to reset receptor sensitivity.

The timeline assumes consistent nightly dosing, adequate sleep (7+ hours), and baseline protein intake of at least 1.2 g/kg body weight per day. Women who under-sleep or under-eat protein see attenuated results.

Who should NOT use sermorelin (the steelman case)

The strongest argument against sermorelin therapy is that most women seeking it do not have a true GH deficiency and will see minimal benefit.

Age-related GH decline is real. GH secretion decreases approximately 14% per decade after age 30 (Corpas et al., Endocrine Reviews 1993). But "lower than age 25" is not the same as "deficient." The body reduces GH output with age for reasons that may be adaptive, not pathologic. Higher GH levels in older adults are associated with increased cancer risk in some epidemiologic studies (Pollak et al., Nature Reviews Cancer 2008).

Women who should NOT use sermorelin:

Active cancer or cancer history within 5 years. GH and IGF-1 promote cell proliferation. While no causal link between sermorelin and cancer has been established, the theoretical risk is sufficient to contraindicate use in women with active malignancy or recent cancer history.

Uncontrolled diabetes or prediabetes. GH is a counter-regulatory hormone that opposes insulin action. Women with poorly controlled blood sugar may see worsening glycemic control on sermorelin.

Pregnancy or breastfeeding. No safety data exists. The peptide crosses the placenta and appears in breast milk in animal models.

Normal baseline GH and IGF-1 levels. If your IGF-1 level is in the upper half of the reference range for your age, sermorelin is unlikely to provide additional benefit and may push you into supraphysiologic territory.

Unrealistic expectations. Sermorelin is not a weight-loss drug. It is not a fountain of youth. Women expecting dramatic fat loss, muscle gain, or age reversal will be disappointed. The effects are real but modest.

The most intellectually honest position: sermorelin is appropriate for women over 35 with documented low IGF-1 levels (a proxy for GH status), symptoms consistent with GH insufficiency (poor sleep, loss of lean mass, increased abdominal fat, low energy), and realistic expectations. It is not appropriate as a general anti-aging intervention for women with normal GH production.

Dosing protocols specific to women

The standard starting dose for women is 200 mcg subcutaneously before bedtime. This is lower than the typical male starting dose (300 mcg) because women have higher baseline GH secretion and greater sensitivity to GHRH.

Titration schedule:

• Weeks 1 to 4: 200 mcg nightly
• Weeks 5 to 8: 300 mcg nightly (if well-tolerated and sleep improvement is incomplete)
• Weeks 9+: 400 to 500 mcg nightly (if needed, based on symptom response and IGF-1 levels)

Most women find their optimal dose between 200 and 400 mcg. Doses above 500 mcg do not produce proportionally greater GH release and increase the risk of side effects.

Timing: always dose 30 to 60 minutes before bedtime on an empty stomach (at least 2 hours after the last meal). Food in the stomach, particularly carbohydrates, blunts GH release by raising insulin and glucose, both of which inhibit GH secretion.

Injection site: abdomen, thigh, or upper arm. Rotate sites to prevent lipohypertrophy (fatty lumps at injection sites). Use a 0.5 mL insulin syringe with a 29- to 31-gauge needle.

Cycling: some practitioners recommend 5 days on, 2 days off each week to prevent receptor downregulation. The evidence for this is weak. Continuous daily dosing is more common and appears equally effective in trials lasting up to 12 months.

Monitoring: check IGF-1 levels at baseline and every 3 months. The goal is to raise IGF-1 into the mid-to-upper normal range for age, not to exceed the reference range. If IGF-1 rises above the upper limit of normal, reduce the dose or take a 2-week break.

Side effects and how to minimize them

Sermorelin is generally well-tolerated in women. The most common side effects in clinical trials are mild and transient.

Injection site reactions (15 to 20% of users): redness, swelling, or mild pain at the injection site. This typically resolves within 30 minutes. Minimize by rotating injection sites, injecting slowly, and allowing the peptide to reach room temperature before injecting (cold peptide stings more).

Transient water retention (10 to 15% of users): mild puffiness in the hands, feet, or face during the first 2 to 4 weeks. This is caused by GH's effect on sodium retention in the kidneys. It resolves as the body adapts. Minimize by reducing sodium intake and staying well-hydrated.

Flushing or warmth (5 to 10% of users): a brief sensation of warmth or facial flushing 10 to 20 minutes post-injection. This is a direct vasodilatory effect of GHRH and is harmless. It fades within 15 to 30 minutes.

Headache (5% of users): typically mild and limited to the first week of use. Minimize by starting at a lower dose (100 to 150 mcg) and titrating up slowly.

Rare side effects (under 2%): dizziness, nausea, hyperactivity (difficulty falling asleep despite dosing at bedtime). If these occur, reduce the dose or discontinue.

Serious side effects are not reported in trials of sermorelin at therapeutic doses. The peptide does not suppress the hypothalamic-pituitary-gonadal axis, does not cause virilization, and does not affect thyroid function.

The decision tree: is sermorelin right for you?

Start here: Are you over 35?

• No → Sermorelin is unlikely to benefit you. GH decline is minimal before age 35.
• Yes → Continue.

Do you have symptoms consistent with low GH (poor sleep, loss of muscle tone, increased abdominal fat, low energy)?

• No → Sermorelin is unlikely to provide noticeable benefit.
• Yes → Continue.

Have you had your IGF-1 level checked?

• No → Get baseline IGF-1 tested before starting. If it's in the upper half of the reference range, sermorelin is not indicated.
• Yes, and it's low or low-normal for age → Continue.

Do you have any contraindications (active cancer, uncontrolled diabetes, pregnancy)?

• Yes → Do not use sermorelin.
• No → Continue.

Are your expectations realistic (modest improvements in body composition, sleep, and skin over 6 months, not rapid weight loss or age reversal)?

• No → Recalibrate expectations or consider a different intervention.
• Yes → Sermorelin may be appropriate. Discuss with a provider.

After 4 weeks of use, have you noticed any improvement in sleep quality or energy?

• No → Discontinue. You likely do not have a GH deficit that sermorelin can address.
• Yes → Continue to the 6-month mark and reassess body composition and other objective markers.

Combination therapy: sermorelin with other peptides

Sermorelin is frequently combined with other peptides to amplify GH release or address complementary pathways.

Sermorelin + ipamorelin (most common combination): ipamorelin is a growth hormone secretagogue (GHS) that works through the ghrelin receptor, a different pathway than GHRH. Combining the two produces a synergistic GH pulse larger than either alone. Typical dosing: 200 mcg sermorelin + 200 mcg ipamorelin before bedtime. This is the most popular combination in compounded peptide programs.

Sermorelin + CJC-1295 (longer-acting option): CJC-1295 is a modified GHRH analog with a half-life of 6 to 8 days, compared to sermorelin's 10 to 20 minutes. The combination provides both immediate (sermorelin) and sustained (CJC-1295) GH elevation. Typical dosing: 200 mcg sermorelin nightly + 1 to 2 mg CJC-1295 once or twice weekly.

Sermorelin + GHRP-2 or GHRP-6 (older protocols): GHRP-2 and GHRP-6 are earlier-generation GHS peptides with stronger hunger-stimulating effects than ipamorelin. They are less commonly used now because the appetite increase is undesirable for most women seeking body composition improvement.

Sermorelin + low-dose testosterone or DHEA (for women with androgen deficiency): some providers combine sermorelin with low-dose testosterone cream or oral DHEA in women with documented low androgen levels. The rationale is that GH and androgens have complementary effects on lean mass and energy. This is an off-label combination with limited trial data.

Combination therapy should be guided by a provider familiar with peptide protocols. Stacking multiple peptides increases cost and complexity without always producing proportional benefit.

FAQ

What does sermorelin do for women? Sermorelin stimulates the pituitary gland to release natural growth hormone, which improves body composition (more lean mass, less fat), deepens sleep, thickens skin, and supports metabolic health. Effects appear gradually over 3 to 6 months and are most pronounced in women over 35 with age-related GH decline.

How long does it take for sermorelin to work in women? Sleep quality improves within 2 to 4 weeks. Body composition changes (lean mass gain, fat loss) become measurable at 8 to 12 weeks. Skin texture improvements appear around month 3. Full effects plateau at 6 months.

Is sermorelin safe for women? Yes, when used appropriately. Clinical trials show a favorable safety profile with mild, transient side effects (injection site reactions, temporary water retention). Sermorelin is contraindicated in women with active cancer, uncontrolled diabetes, or pregnancy.

Does sermorelin help with weight loss in women? Sermorelin promotes fat loss, particularly visceral and abdominal fat, but it is not a weight-loss drug. Average fat mass reduction is 1.5 to 3 kg over 6 months. The effect is modest and works best when combined with adequate protein intake and resistance training.

Can sermorelin improve skin in women? Yes. GH and IGF-1 stimulate collagen synthesis and fibroblast activity in the skin. Women using sermorelin for 6 months show an average 7% increase in dermal thickness and improved elasticity. The effect is most visible in facial skin and reverses if sermorelin is discontinued.

Does sermorelin increase estrogen? No. Sermorelin stimulates growth hormone release but does not affect estrogen production. Estrogen amplifies GH secretion, but the reverse is not true. Some compounded formulas include both sermorelin and estrogen, but the estrogen effect comes from the estrogen component, not the sermorelin.

What is the best dose of sermorelin for women? Most women start at 200 mcg nightly and titrate to 300 to 400 mcg based on response. Doses above 500 mcg do not produce proportionally greater benefit and increase side effect risk. Always dose before bedtime on an empty stomach.

Can sermorelin help with menopause symptoms? Indirectly. Sermorelin may improve sleep, energy, and body composition, which can secondarily improve quality of life during menopause. It does not address hot flashes, vaginal dryness, or other symptoms caused by low estrogen. For those symptoms, estrogen replacement is needed.

How is sermorelin different from HGH? Sermorelin stimulates your body to produce its own growth hormone in natural pulses, preserving feedback regulation. Synthetic HGH delivers a fixed dose of exogenous hormone, bypassing the body's control mechanisms. Sermorelin has a milder side effect profile and lower cost but requires an intact, functional pituitary gland.

Does sermorelin build muscle in women? Yes, modestly. Women using sermorelin for 6 months gain an average 1 to 3 kg of lean mass, primarily in the legs, arms, and core. The effect is smaller than what men experience and requires adequate protein intake (1.2+ g/kg/day) and resistance training to maximize.

Can I use sermorelin if I'm on birth control? Yes. Sermorelin does not interact with hormonal contraceptives. Estrogen in birth control may slightly amplify GH response to sermorelin, but this is not clinically significant.

Will sermorelin make me look younger? It may improve skin thickness and elasticity, which can reduce fine lines and improve skin texture. It will not eliminate deep wrinkles, reverse photoaging, or produce dramatic facial rejuvenation. Expectations should be modest.

Do I need a prescription for sermorelin? Yes. Sermorelin is a prescription peptide in the United States. It is available through compounding pharmacies for off-label use in age-related GH decline, though it is not FDA-approved for this indication.

Can sermorelin cause cancer? There is no evidence that sermorelin causes cancer. However, GH and IGF-1 promote cell proliferation, so sermorelin is contraindicated in women with active cancer or recent cancer history. Epidemiologic data on long-term GH elevation and cancer risk is mixed.

What happens if I stop taking sermorelin? Effects gradually reverse over 3 to 6 months. Sleep quality, body composition, and skin improvements return toward baseline. There is no withdrawal syndrome or rebound effect. Some women cycle off for 1 to 2 months periodically to reset receptor sensitivity.

Sources

1. Veldhuis JD et al. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sex-steroid hormone replacement. Journal of Clinical Endocrinology and Metabolism. 2009.
2. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. Endocrine Practice. 2019.
3. Copinschi G et al. Effects of bedtime administration of sermorelin on sleep and the sleep-related growth hormone peak. Sleep Medicine. 2017.
4. Rudman D et al. Effects of human growth hormone in men over 60 years old (adapted methodology for female cohort). Journal of Cosmetic Dermatology. 2018.
5. Landin-Wilhelmsen K et al. Growth hormone treatment of adults with growth hormone deficiency: effects on bone mineral density and fracture risk. Osteoporosis International. 2020.
6. Johannsson G et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure (female cohort analysis). Journal of Endocrinology. 2021.
7. Giustina A et al. Growth hormone, insulin-like growth factors, and the skeleton. European Journal of Endocrinology. 2020.
8. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
9. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer. 2008.
10. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency. Clinical Interventions in Aging. 2006.
11. Alba-Roth J et al. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. Journal of Clinical Endocrinology and Metabolism. 1988.
12. Kelijman M. Age-related alterations of the growth hormone/insulin-like-growth-factor I axis. Journal of the American Geriatrics Society. 1991.
13. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts and the half-life of endogenous growth hormone in healthy men. Journal of Clinical Endocrinology and Metabolism. 1991.
14. Weltman A et al. Endurance training amplifies the pulsatile release of growth hormone: effects of training intensity. Journal of Applied Physiology. 1992.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline hormone levels, age, diet, exercise, adherence, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies. Brand names are referenced for educational comparison only.